Subscribe to Newsletter

Illumina

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other institutions around the globe. For further details please visit www.illumina.com.

Contact Information:

Illumina Cambridge Ltd, Granta Park, Great Abington, Cambridge CB21 6GP, United Kingdom
Telephone:  + 44 (0) 1 223 824 800
Contact request: https://emea.illumina.com/forms/contact_request.html

Company website (UK)

Content by Illumina:

Subspecialties Oncology

A New Class of Villains

| Sponsored by Illumina

An ever-watchful Methylation Man unveils the true power of epigenetic mapping – and truth wins the day

Subspecialties Oncology

Methylation Man – Origin Story

| Sponsored by Illumina

Our hero meets his nemesis: primary unknown

Diagnostics Biochemistry and molecular biology

In Profile

| Sponsored by Illumina | 2 min read

Exploring the relative merits of comprehensive genomic profiling and targeted panel testing in precision diagnostics for oncology

Subspecialties Oncology

I’m Methylation Man

| Sponsored by Illumina

Understanding DNA methylation is a real super power – and it's as simple as ready, set, sort (#nocapes)

Diagnostics Oncology

The Hype Over HRD Testing

| Liv Gaskill | 3 min read

Homologous recombination deficiency is a crucial predictive biomarker in certain cancer types – and it’s time to get on board

Subspecialties Oncology

Comprehensive Genomic Profiling – A New Look

| Sponsored by Illumina

With comprehensive genomic profiling, are we moving closer to personalized therapy for all cancer patients?

Diagnostics Omics

New e-book: Crushing cancer one genomic profile at a time!

| Sponsored by Illumina

Delve into a wealth of content within this new e-book by Illumina

Inside the Lab Technology and innovation

A New Dawn for Comprehensive Genomic Profiling with TruSight™ Oncology 500

| Sponsored by Illumina

Results from early access trials demonstrate the reproducibility and reliability of a pan-cancer next-generation sequencing assay

Inside the Lab Liquid biopsy

Liquid Biopsy Insights into Cancer

| Sponsored by Illumina

Liquid biopsy is minimally invasive and easily accessible – but what information can a new multiplexed assay provide from circulating tumor DNA?

Subspecialties Oncology

TruSight™ Oncology 500: Enabling Comprehensive Genomic Profiling for Every Laboratory

| Sponsored by Illumina

Comprehensively exploring tumor samples to analyze hundreds of current and emerging cancer-related biomarkers

Announcing TruSight™ Oncology 500 for tumor mutational burden assessment

| Contributed by Illumina

Comprehensive NGS assay profiles both DNA and RNA variants in solid tumors

| Contributed by Illumina

Webinars on Demand

Diagnostics Liquid biopsy

Clinical implications of comprehensive genomic profiling on liquid biopsy for lung cancer patients

| Sponsored by Illumina

In this webinar, Dr Federico Cappuzzo will speak about clinical implications of liquid biopsy-based CGP for lung cancer patients, discussing current clinical evidence and sharing his vision on future applications.

Outside the Lab Regulation and standards

Illumina - Your partner in the transition to IVDR

| Sponsored by Illumina

Join Illumina for an educational webinar on the new EU IVD Regulation.

Subspecialties Oncology

Optimizing Comprehensive Genomic Profiling and NTRK Fusion Detection in Advanced Cancers

| Sponsored by Illumina

This virtual interactive case-based expert forum will be discussing NTRK fusion detection and therapeutic management of NTRK fusion driven advanced cancers.

Diagnostics Liquid biopsy

Comprehensive genomic profiling from liquid biopsy samples in clinical trials

| Sponsored by Illumina

Clinical trials are increasingly using liquid biopsy samples to complement or as an alternative to invasive tissue sample collections.

Subspecialties Genetics and epigenetics

Fast and robust implementation of an NGS solution in genomic profiling

| Sponsored by Illumina

Recent developments in cancer research, and rapidly increasing options for personalized therapeutics, showed the need for a comprehensive, fast and robust way to analyze the genetic information of DNA and RNA variants.

Subspecialties Oncology

Principles and considerations for Tumor Mutational Burden (TMB) testing

| Sponsored by Illumina

In this webinar, Albrecht Stenzinger will discuss the principles of using nextgeneration sequencing (NGS) to identify the number of genetic alterations in a tumor.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register